T-Cell progenitors as a new immunotherapy to bypass hurdles of allogeneic hematopoietic stem cell transplantation

Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of preference for numerous malignant and non-malignant hemopathies. The outcome of this approach is significantly hampered by not only graft-versus-host disease (GvHD), but also infections and relapses that may occur because...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Gaudeaux, Pierre (VerfasserIn) , Moirangthem, Ranjita Devi (VerfasserIn) , Bauquet, Aurélie (VerfasserIn) , Simons, Laura (VerfasserIn) , Joshi, Akshay (VerfasserIn) , Cavazzana, Marina (VerfasserIn) , Nègre, Olivier (VerfasserIn) , Soheili, Shabi (VerfasserIn) , André, Isabelle (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 07 July 2022
In: Frontiers in immunology
Year: 2022, Jahrgang: 13
ISSN:1664-3224
DOI:10.3389/fimmu.2022.956919
Online-Zugang:Resolving-System, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2022.956919
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fimmu.2022.956919
Volltext
Verfasserangaben:Pierre Gaudeaux, Ranjita Devi Moirangthem, Aurélie Bauquet, Laura Simons, Akshay Joshi, Marina Cavazzana, Olivier Nègre, Shabi Soheili and Isabelle André

MARC

LEADER 00000caa a2200000 c 4500
001 1822269520
003 DE-627
005 20230906161159.0
007 cr uuu---uuuuu
008 221114s2022 xx |||||o 00| ||eng c
024 7 |a 10.3389/fimmu.2022.956919  |2 doi 
035 |a (DE-627)1822269520 
035 |a (DE-599)KXP1822269520 
035 |a (OCoLC)1361692940 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Gaudeaux, Pierre  |e VerfasserIn  |0 (DE-588)1272727866  |0 (DE-627)1822278716  |4 aut 
245 1 0 |a T-Cell progenitors as a new immunotherapy to bypass hurdles of allogeneic hematopoietic stem cell transplantation  |c Pierre Gaudeaux, Ranjita Devi Moirangthem, Aurélie Bauquet, Laura Simons, Akshay Joshi, Marina Cavazzana, Olivier Nègre, Shabi Soheili and Isabelle André 
264 1 |c 07 July 2022 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 14.11.2022 
520 |a Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of preference for numerous malignant and non-malignant hemopathies. The outcome of this approach is significantly hampered by not only graft-versus-host disease (GvHD), but also infections and relapses that may occur because of persistent T-cell immunodeficiency following transplantation. Reconstitution of a functional T-cell repertoire can take more than 1 year. Thus, the major challenge in the management of allogeneic HSCT relies on the possibility of shortening the window of immune deficiency through the acceleration of T-cell recovery, with diverse, self-tolerant, and naïve T cells resulting from de novo thymopoiesis from the donor cells. In this context, adoptive transfer of cell populations that can give rise to mature T cells faster than HSCs while maintaining a safety profile compatible with clinical use is of major interest. In this review, we summarize current advances in the characterization of thymus seeding progenitors, and their ex vivo generated counterparts, T-cell progenitors. Transplantation of the latter has been identified as a worthwhile approach to shorten the period of immune deficiency in patients following allogeneic HSCT, and to fulfill the clinical objective of reducing morbimortality due to infections and relapses. We further discuss current opportunities for T-cell progenitor-based therapy manufacturing, including iPSC cell sources and off-the-shelf strategies. These opportunities will be analyzed in the light of results from ongoing clinical studies involving T-cell progenitors. 
700 1 |a Moirangthem, Ranjita Devi  |e VerfasserIn  |4 aut 
700 1 |a Bauquet, Aurélie  |e VerfasserIn  |4 aut 
700 1 |a Simons, Laura  |d 1981-  |e VerfasserIn  |0 (DE-588)1117114295  |0 (DE-627)871033380  |0 (DE-576)478767692  |4 aut 
700 1 |a Joshi, Akshay  |e VerfasserIn  |4 aut 
700 1 |a Cavazzana, Marina  |e VerfasserIn  |4 aut 
700 1 |a Nègre, Olivier  |e VerfasserIn  |4 aut 
700 1 |a Soheili, Shabi  |e VerfasserIn  |4 aut 
700 1 |a André, Isabelle  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in immunology  |d Lausanne : Frontiers Media, 2010  |g 13(2022), Artikel-ID 956919  |h Online-Ressource  |w (DE-627)657998354  |w (DE-600)2606827-8  |w (DE-576)343624834  |x 1664-3224  |7 nnas  |a T-Cell progenitors as a new immunotherapy to bypass hurdles of allogeneic hematopoietic stem cell transplantation 
773 1 8 |g volume:13  |g year:2022  |g elocationid:956919  |g extent:9  |a T-Cell progenitors as a new immunotherapy to bypass hurdles of allogeneic hematopoietic stem cell transplantation 
856 4 0 |u https://doi.org/10.3389/fimmu.2022.956919  |x Resolving-System  |x Verlag  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.frontiersin.org/articles/10.3389/fimmu.2022.956919  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20221114 
993 |a Article 
994 |a 2022 
998 |g 1117114295  |a Simons, Laura  |m 1117114295:Simons, Laura  |d 910000  |d 910100  |e 910000PS1117114295  |e 910100PS1117114295  |k 0/910000/  |k 1/910000/910100/ 
999 |a KXP-PPN1822269520  |e 421027061X 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Pierre Gaudeaux, Ranjita Devi Moirangthem, Aurélie Bauquet, Laura Simons, Akshay Joshi, Marina Cavazzana, Olivier Nègre, Shabi Soheili and Isabelle André"]},"origin":[{"dateIssuedDisp":"07 July 2022","dateIssuedKey":"2022"}],"id":{"eki":["1822269520"],"doi":["10.3389/fimmu.2022.956919"]},"physDesc":[{"extent":"9 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1664-3224"],"zdb":["2606827-8"],"eki":["657998354"]},"origin":[{"publisher":"Frontiers Media","dateIssuedKey":"2010","dateIssuedDisp":"2010-","publisherPlace":"Lausanne"}],"recId":"657998354","language":["eng"],"note":["Gesehen am 07.11.13"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"T-Cell progenitors as a new immunotherapy to bypass hurdles of allogeneic hematopoietic stem cell transplantationFrontiers in immunology","part":{"year":"2022","text":"13(2022), Artikel-ID 956919","volume":"13","extent":"9"},"pubHistory":["1.2010 -"],"title":[{"title":"Frontiers in immunology","title_sort":"Frontiers in immunology"}]}],"person":[{"family":"Gaudeaux","given":"Pierre","display":"Gaudeaux, Pierre","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Moirangthem","given":"Ranjita Devi","display":"Moirangthem, Ranjita Devi","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Bauquet, Aurélie","given":"Aurélie","family":"Bauquet"},{"family":"Simons","given":"Laura","roleDisplay":"VerfasserIn","display":"Simons, Laura","role":"aut"},{"role":"aut","display":"Joshi, Akshay","roleDisplay":"VerfasserIn","given":"Akshay","family":"Joshi"},{"family":"Cavazzana","given":"Marina","roleDisplay":"VerfasserIn","display":"Cavazzana, Marina","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Nègre, Olivier","role":"aut","family":"Nègre","given":"Olivier"},{"display":"Soheili, Shabi","roleDisplay":"VerfasserIn","role":"aut","family":"Soheili","given":"Shabi"},{"role":"aut","roleDisplay":"VerfasserIn","display":"André, Isabelle","given":"Isabelle","family":"André"}],"title":[{"title":"T-Cell progenitors as a new immunotherapy to bypass hurdles of allogeneic hematopoietic stem cell transplantation","title_sort":"T-Cell progenitors as a new immunotherapy to bypass hurdles of allogeneic hematopoietic stem cell transplantation"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 14.11.2022"],"language":["eng"],"recId":"1822269520"} 
SRT |a GAUDEAUXPITCELLPROGE0720